AR040737A1 - Administracion oral de calcitonina - Google Patents

Administracion oral de calcitonina

Info

Publication number
AR040737A1
AR040737A1 AR20030102740A ARP030102740A AR040737A1 AR 040737 A1 AR040737 A1 AR 040737A1 AR 20030102740 A AR20030102740 A AR 20030102740A AR P030102740 A ARP030102740 A AR P030102740A AR 040737 A1 AR040737 A1 AR 040737A1
Authority
AR
Argentina
Prior art keywords
oral
administration
calcitonin
calcitonine
pharmaceutical compositions
Prior art date
Application number
AR20030102740A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR040737A1 publication Critical patent/AR040737A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Método particular para la administración oral de composiciones farmacéuticas que comprenden calcitonina en combinación con agentes de suministro oral, antes del consumo de alimento en seres humanos, y un método de tratamiento de desórdenes que responden a la acción de la calcitonina, empleando este método de administración, también se dan a conocer composiciones farmacéuticas orales de calcitonina con proporciones particulares de la cantidad de agente de suministro oral a la cantidad de calcitonina.
AR20030102740A 2002-08-01 2003-07-30 Administracion oral de calcitonina AR040737A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40013902P 2002-08-01 2002-08-01

Publications (1)

Publication Number Publication Date
AR040737A1 true AR040737A1 (es) 2005-04-20

Family

ID=31495795

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102740A AR040737A1 (es) 2002-08-01 2003-07-30 Administracion oral de calcitonina

Country Status (19)

Country Link
US (2) US20060135402A1 (es)
EP (1) EP1526871A1 (es)
JP (4) JP2005535689A (es)
KR (6) KR20160113319A (es)
CN (1) CN1671418A (es)
AR (1) AR040737A1 (es)
AU (1) AU2003260346B2 (es)
BR (1) BR0313177A (es)
CA (1) CA2494212A1 (es)
IL (1) IL166337A (es)
MX (1) MXPA05001266A (es)
NO (1) NO20051023L (es)
NZ (1) NZ537944A (es)
PE (1) PE20040724A1 (es)
PL (1) PL373143A1 (es)
RU (1) RU2355417C2 (es)
TW (1) TWI307279B (es)
WO (1) WO2004012772A1 (es)
ZA (1) ZA200500516B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080049128A (ko) 2005-09-19 2008-06-03 에미스페어 테크놀로지스, 인코포레이티드 Ｎ-(5-클로로살리실로일)-8-아미노카프릴산 이나트륨염의결정형
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
ES2365648T3 (es) * 2007-03-02 2011-10-07 Novartis Ag Administración oral de una calcitonina.
WO2009019307A2 (en) * 2007-08-09 2009-02-12 Novartis Ag Oral calcitonin compositions and applications thereof
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
EP2461803B1 (en) * 2009-08-03 2018-10-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
CN107427481A (zh) * 2015-02-09 2017-12-01 安特拉贝欧有限公司 骨质疏松症的治疗
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
EP4326329A1 (en) 2021-04-22 2024-02-28 Civi Biopharma, Inc. Oral delivery of oligonucleotides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
WO2000059480A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making
EP1175390B1 (en) * 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Also Published As

Publication number Publication date
JP2016056190A (ja) 2016-04-21
US20060135402A1 (en) 2006-06-22
IL166337A (en) 2011-10-31
MXPA05001266A (es) 2005-04-28
JP2011026348A (ja) 2011-02-10
BR0313177A (pt) 2005-06-14
KR20160113319A (ko) 2016-09-28
US7569539B2 (en) 2009-08-04
KR20050032101A (ko) 2005-04-06
PL373143A1 (en) 2005-08-22
TWI307279B (en) 2009-03-11
JP2005535689A (ja) 2005-11-24
KR20140084354A (ko) 2014-07-04
KR20170097232A (ko) 2017-08-25
RU2355417C2 (ru) 2009-05-20
KR20110014690A (ko) 2011-02-11
PE20040724A1 (es) 2004-12-06
NO20051023L (no) 2005-04-27
ZA200500516B (en) 2006-07-26
US20070232524A1 (en) 2007-10-04
AU2003260346B2 (en) 2007-12-13
CA2494212A1 (en) 2004-02-12
IL166337A0 (en) 2006-01-16
TW200408409A (en) 2004-06-01
JP2014062112A (ja) 2014-04-10
NZ537944A (en) 2006-11-30
CN1671418A (zh) 2005-09-21
JP5941035B2 (ja) 2016-06-29
WO2004012772A1 (en) 2004-02-12
KR20130004389A (ko) 2013-01-09
RU2005105691A (ru) 2006-01-20
AU2003260346A1 (en) 2004-02-23
EP1526871A1 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
DE60322436D1 (de) Verabreichung von capsaicinoiden
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
ECSP056159A (es) Composición de fármaco conjugado
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
ATE268595T1 (de) Formulierungen mit gesteuerter freisetzung, die einen schnellen eintritt und einen schnellen abfall der wirksamen arzneistoffplasmakonzentrationen haben
MXPA05006670A (es) Administracion de capsaicinoides.
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
AR040737A1 (es) Administracion oral de calcitonina
TW200642704A (en) Oral drug delivery system and methods of use thereof
ATE333896T1 (de) Vaskularisierungsinhibitoren
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
DE602008006700D1 (es)
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
ES2195939T3 (es) Composicion para prevencion y/o tratamiento de trastornos circulatorios que comprende derivados de l-carnitina y extractos de ginkgo biloba.
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
AR020853A1 (es) Utilizacion de insaponificables de aceites vegetales para la preparacion de un medicamento que estimula la expresion del tgf-beta o la expresion delinhibidor pai-1 del activador del plasminogeno.
AR015956A1 (es) Composiciones de citoquinas oromucosales y usos de las mismas
AR018376A1 (es) Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
SE0203817D0 (sv) New composition
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer

Legal Events

Date Code Title Description
FB Suspension of granting procedure